leadf
logo-loader
viewCardiex Ltd

Atcor Medical Holdings Limited wins three new contracts

The new deals are with major international pharmaceutical companies.

MedicalMonitor.jpg
Heart failure is a growing focus for AtCor’s SphygmoCor technology

Atcor Medical Holdings Limited (ASX:ACG) has signed three new contracts worth circa $800,00 to supply its SphygmoCor systems and clinical trial support services.

AtCor develops and markets products for the early detection of target organ damage and management of cardiovascular and renal diseases.

Its SphygmoCor technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity.

The new deals are with major international pharmaceutical companies.

The clinical trials, for two existing clients and one new client, will be conducted in the U.S., Europe and Japan and run for 12-17 months.

Two studies are Phase II trials which if successful are expected to open a larger opportunity for AtCor when the trials progress to Phase III.

These include a trial in the acute coronary syndrome field, which is a condition brought on by the sudden reduction of blood to the heart, and a trial in the heart failure field.

Heart failure is a chronic and increasingly costly disease, and a growing focus for AtCor’s SphygmoCor technology in the clinic.

SphygmoCor has been specified for additional heart failure trials in FY2018 with other companies, and negotiations are underway.

SphygmoCor has also recently been used in drug trials for inflammatory disorders and type 2 diabetes, further expanding the company’s addressable market.

Quick facts: Cardiex Ltd

Price: 0.055 AUD

ASX:CDX
Market: ASX
Market Cap: $46.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiex Ltd named herein, including the promotion by the Company of Cardiex Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CardieX Limited signs disruptive deal with Chinese medical device company Andon

CardieX Limited (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive with news the company has entered a co-development and commercial partnership agreement with Andon. Andon is one of China’s largest manufacturers of home-use medical electronic devices. Cooper talks about the deal...

on 9/9/20

2 min read